Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

Template:SubstanceBox/LSD: Difference between revisions

From PsychonautWiki Archive
Jump to navigation Jump to search
← Older edit
>Graham
m wiki ref formatting
>Quack
The current citation for the bioavailability for the Sublingual ROA is actually referencing the "... assuming [of] an oral bioavailability of 71%..." on page 5 and 6. Upon further research there exist a more concurrent article to contrast this figure, concluding a new bioavailability closer to 100% on page 1149.
 
Line 50: Line 50:
     <!-- Dosage/Duration per ROA -->
     <!-- Dosage/Duration per ROA -->


     |OralROA=false
     |OralROA=true
     |OralROA_Collapsed=true
     |OralROA_Collapsed=false
     |OralROA_Caption=
     |OralROA_Caption=
     |OralROA_Bioavailability=
     |OralROA_Bioavailability=[[Sublingual min bioavailability::92]]% - [[Sublingual max bioavailability::100]]%<ref>{{cite journal | vauthors=((Grumann, Christina, et al.)) | title=Pharmacokinetics and subjective effects of 1P-LSD in humans after oral and intravenous administration |  journal=Drug Testing and Analysis | volume=12 | issue=8 | date= January 2016 | pages=1144-1153 | url=https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.2821 | doi=https://doi.org/10.1002/dta.2821}}</ref>
     |OralROA_Threshold=
     |OralROA_Threshold=
     |OralROA_Light=
     |OralROA_Light=
Line 71: Line 71:
     |SublingualROA_Collapsed=false
     |SublingualROA_Collapsed=false
     |SublingualROA_Caption=
     |SublingualROA_Caption=
     |SublingualROA_Bioavailability=[[Sublingual min bioavailability::71]]% - [[Sublingual max bioavailability::71]]%<ref>{{cite journal | vauthors=((Dolder, P. C.)), ((Schmid, Y.)), ((Haschke, M.)), ((Rentsch, K. M.)), ((Liechti, M. E.)) | journal=International Journal of Neuropsychopharmacology | title=Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans | volume=19 | issue=1 | pages=1–7 | date= January 2016 | url=https://academic.oup.com/ijnp/article-lookup/doi/10.1093/ijnp/pyv072 | issn=1461-1457 | doi=10.1093/ijnp/pyv072}}</ref>
     |SublingualROA_Bioavailability=
     |SublingualROA_Microdose=
     |SublingualROA_Microdose=
     |SublingualROA_Threshold=[[Sublingual threshold dose::15]] [[Sublingual dose units::µg]]  
     |SublingualROA_Threshold=[[Sublingual threshold dose::15]] [[Sublingual dose units::µg]]  

Latest revision as of 02:20, 8 May 2024

SubstanceBox/LSD
Chemical Nomenclature
Common names LSD, LSD-25, Lucy, L, Acid, Cid, Tabs, Blotter
Substitutive name d-Lysergic acid diethylamide
Systematic name (6aR,9R)-N,N-Diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide
Class Membership
Psychoactive class Psychedelic
Chemical class Lysergamide
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



⇣ Oral
Dosage
Bioavailability 92% - 100%[1]
Duration


⇣ Sublingual
Dosage
Threshold 15 µg
Light 15 - 75 µg
Common 75 - 150 µg
Strong 150 - 300 µg
Heavy 300 µg +
Duration
Total 8 - 12 hours
Onset 15 - 30 minutes
Come up 45 - 90 minutes
Peak 3 - 5 hours
Offset 3 - 5 hours
After effects 12 - 48 hours







DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

  1. ↑ Grumann, Christina, et al. (January 2016). "Pharmacokinetics and subjective effects of 1P-LSD in humans after oral and intravenous administration". Drug Testing and Analysis. 12 (8): 1144–1153. doi:https://doi.org/10.1002/dta.2821 Check |doi= value (help). 
Retrieved from "http://psy.st/w/index.php?title=Template:SubstanceBox/LSD&oldid=137732"